122 related articles for article (PubMed ID: 29617136)
1. BACE1: Now We Can See You.
Bongarzone S; Gee AD
J Med Chem; 2018 Apr; 61(8):3293-3295. PubMed ID: 29617136
[TBL] [Abstract][Full Text] [Related]
2. The evolution of amidine-based brain penetrant BACE1 inhibitors.
Oehlrich D; Prokopcova H; Gijsen HJ
Bioorg Med Chem Lett; 2014 May; 24(9):2033-45. PubMed ID: 24704031
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain.
Zhang L; Chen L; Dutra JK; Beck EM; Nag S; Takano A; Amini N; Arakawa R; Brodney MA; Buzon LM; Doran SD; Lanyon LF; McCarthy TJ; Bales KR; Nolan CE; O'Neill BT; Schildknegt K; Halldin C; Villalobos A
J Med Chem; 2018 Apr; 61(8):3296-3308. PubMed ID: 29356535
[TBL] [Abstract][Full Text] [Related]
4. RO6807936 as a novel positron emission tomography (PET) radiotracer for in vitro and in vivo visualization and quantification of beta-site amyloid precursor protein cleaving enzyme (BACE1) in the rodent and baboon brain.
Honer M; Polara A; Kuwabara H; Jacobsen H; Pähler A; Hartung T; Caruso A; Esterhazy D; Stoffel M; Dannals RF; Wong DF; Borroni E; Gobbi LC
J Labelled Comp Radiopharm; 2023 Jul; 66(9):222-236. PubMed ID: 37095603
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease.
Deleye S; Waldron AM; Verhaeghe J; Bottelbergs A; Wyffels L; Van Broeck B; Langlois X; Schmidt M; Stroobants S; Staelens S
J Nucl Med; 2017 Dec; 58(12):1977-1983. PubMed ID: 28611242
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, radiolabeling, and evaluation of a potent β-site APP cleaving enzyme (BACE1) inhibitor for PET imaging of BACE1 in vivo.
Pan L; He Q; Wu Y; Zhang N; Cai H; Yang B; Wang Y; Li Y; Wu X
Bioorg Med Chem Lett; 2022 Mar; 59():128543. PubMed ID: 35031452
[TBL] [Abstract][Full Text] [Related]
7. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Moussa CE
Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Analysis of
Takano A; Chen L; Nag S; Brodney MA; Arakawa R; Chang C; Amini N; Doran SD; Dutra JK; McCarthy TJ; Nolan CE; O'Neill BT; Villalobos A; Zhang L; Halldin C
J Nucl Med; 2019 Jul; 60(7):992-997. PubMed ID: 30530832
[TBL] [Abstract][Full Text] [Related]
9. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
[TBL] [Abstract][Full Text] [Related]
10. Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine β-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors.
Wu YJ; Guernon J; Shi J; Marcin L; Higgins M; Rajamani R; Muckelbauer J; Lewis H; Chang C; Camac D; Toyn JH; Ahlijanian MK; Albright CF; Macor JE; Thompson LA
J Med Chem; 2016 Sep; 59(18):8593-600. PubMed ID: 27559936
[TBL] [Abstract][Full Text] [Related]
11. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
Barão S; Moechars D; Lichtenthaler SF; De Strooper B
Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
[TBL] [Abstract][Full Text] [Related]
12. β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.
Hilpert H; Guba W; Woltering TJ; Wostl W; Pinard E; Mauser H; Mayweg AV; Rogers-Evans M; Humm R; Krummenacher D; Muser T; Schnider C; Jacobsen H; Ozmen L; Bergadano A; Banner DW; Hochstrasser R; Kuglstatter A; David-Pierson P; Fischer H; Polara A; Narquizian R
J Med Chem; 2013 May; 56(10):3980-95. PubMed ID: 23590342
[TBL] [Abstract][Full Text] [Related]
13. PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [
Arakawa R; Takano A; Stenkrona P; Stepanov V; Nag S; Jahan M; Grybäck P; Bolin M; Chen L; Zhang L; He P; Villalobos A; McCarthy TJ; Halldin C; Varrone A
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2429-2439. PubMed ID: 32140803
[TBL] [Abstract][Full Text] [Related]
14. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
[TBL] [Abstract][Full Text] [Related]
15. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of quinazolinone-based hydrazones with potential use in Alzheimer's disease.
Haghighijoo Z; Firuzi O; Hemmateenejad B; Emami S; Edraki N; Miri R
Bioorg Chem; 2017 Oct; 74():126-133. PubMed ID: 28780149
[TBL] [Abstract][Full Text] [Related]
17. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
[TBL] [Abstract][Full Text] [Related]
18. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans.
May PC; Willis BA; Lowe SL; Dean RA; Monk SA; Cocke PJ; Audia JE; Boggs LN; Borders AR; Brier RA; Calligaro DO; Day TA; Ereshefsky L; Erickson JA; Gevorkyan H; Gonzales CR; James DE; Jhee SS; Komjathy SF; Li L; Lindstrom TD; Mathes BM; Martényi F; Sheehan SM; Stout SL; Timm DE; Vaught GM; Watson BM; Winneroski LL; Yang Z; Mergott DJ
J Neurosci; 2015 Jan; 35(3):1199-210. PubMed ID: 25609634
[TBL] [Abstract][Full Text] [Related]
19. Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice.
Thakker DR; Sankaranarayanan S; Weatherspoon MR; Harrison J; Pierdomenico M; Heisel JM; Thompson LA; Haskell R; Grace JE; Taylor SJ; Albright CF; Shafer LL
J Neurosci; 2015 Apr; 35(17):6931-6. PubMed ID: 25926467
[TBL] [Abstract][Full Text] [Related]
20. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
